CEO Total Pay
$12.8M
FY2023 Summary Compensation, above median
ZNTL FY2023 SEC EDGAR DEF 14A
Zentalis Pharmaceuticals, Inc. CEO pay ratio
The CEO earned $12.8M in FY2023 against median worker pay of $290,791 · Chemicals & Pharmaceuticals.
- State
- NY
- Filing date
- 2024-04-29
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2023
Data updated August 2026
Subscribe to Zentalis Pharmaceuticals, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
44:1
Below Average (Scale: 0–1000:1)
CEO pay
$12.8M
Median worker
$290,791
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Zentalis Pharmaceuticals, Inc. reported a 44:1 CEO-to-worker pay ratio in FY2023 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 44:1
- FY2023 disclosed
- CEO total
- $12.8M
- Summary Compensation Table total
- Median worker
- $290,791
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2023
A component-level pay breakdown is not reported in Zentalis Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Zentalis Pharmaceuticals, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2022–2023. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 44:1
- FY2023
- vs prior FY
- +19:1
- from FY2022 25:1
- CEO $ YoY
- +58%
- $12.8M latest
- Filings shown
- 2
- FY2022–2023
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2022 | $8.1M | - | $324,217 | 25:1 | - |
| 2023 | $12.8M | +58% | $290,791 | 44:1 | +19:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1725160, FY2022–2023. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
44:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$12.8M
Companies in Industry
168
vs. Industry Median
Above
Zentalis Pharmaceuticals, Inc.: MODEST · HEAVY pay ratio
Zentalis Pharmaceuticals, Inc. disclosed 44:1 CEO-to-worker pay and $12.8M CEO total in FY2023. the CEO earned 44× the median employee ($290,791) in FY2023.
Median employee $290,791 (ELITE-MED); MODEST · HEAVY stamps put about 44 median-wage years per CEO year.
Pay Ratio
44:1
Below typical
What FY2023 shows for Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. disclosed 44:1 CEO-to-worker pay and $12.8M CEO total in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Zentalis Pharmaceuticals, Inc.'s $12.8M CEO total is above the $7.9M industry median CEO pay.
Zentalis Pharmaceuticals, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2023
- Total Compensation
- $12.8M
- Median Employee Pay
- $290,791
- Pay Ratio
- 44:1
- Filing Date
- 2024-04-29
Company Info
- Ticker
- ZNTL
- CIK
- 1725160
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- NY
SEC EDGAR DEF 14A for CIK 1725160, FY2023. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Zentalis Pharmaceuticals, Inc. disclosed 44:1 CEO-to-worker pay and $12.8M CEO total in FY2023.
Read with Zentalis Pharmaceuticals, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
Radian Group Inc · HEAVY
ABS(ceo_total_comp) peer at $12.8M (Δ $524 heavier vs Zentalis Pharmaceuticals, Inc.); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Xerox Holdings Corp · HEAVY
ABS(ceo_total_comp) peer at $12.8M (Δ $30K heavier vs Zentalis Pharmaceuticals, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Amkor Technology, Inc. · HEAVY
ABS(ceo_total_comp) peer at $12.8M (Δ $49K heavier vs Zentalis Pharmaceuticals, Inc.); EXTREME · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
ManpowerGroup Inc. · HEAVY
ABS(ceo_total_comp) peer at $12.7M (Δ $81K lighter vs Zentalis Pharmaceuticals, Inc.); MEGA · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Zentalis Pharmaceuticals, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Zentalis Pharmaceuticals, Inc..
Ratio primer · MODEST
Zentalis Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Zentalis Pharmaceuticals, Inc. (CIK 1725160), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.